CAMP4 Therapeutics (CAMP) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Lifecore Biomedical (LFCR) over the past year, gaining 16.7% versus a loss of 4.5%. Lifecore Biomedical is the larger company by market cap ($243.9 million vs $227.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | LFCR |
|---|---|---|
| Share price | $3.62 | $6.44 |
| Market cap | $227.17M | $243.92M |
| 1-day change | -5.73% | -0.08% |
| YTD return | -37.36% | -21.27% |
| 1-year return | +16.72% | -4.45% |
| 5-year return | — | -34.35% |
| EPS (TTM) | $-2.32 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $8.98 |
| 52-week low | $2.86 | $3.63 |
| Distance from 52-week high | -53.29% | -28.34% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +191.99% | -2.41% |
| Average volume | 277.90K | 289.19K |
| Shares outstanding | 62.75M | 37.91M |
| Employees | 48 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed LFCR by 21.2 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
CAMP vs LFCR FAQ
Which is bigger, CAMP4 Therapeutics or Lifecore Biomedical?
Lifecore Biomedical (LFCR) is larger, with a market capitalization of $243.92M compared with $227.17M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or LFCR?
CAMP returned +16.72% over the past 12 months, compared with -4.45% for LFCR (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.